MCID: FML039
MIFTS: 39

Female Reproductive System Disease

Categories: Reproductive diseases

Aliases & Classifications for Female Reproductive System Disease

MalaCards integrated aliases for Female Reproductive System Disease:

Name: Female Reproductive System Disease 12 15 17
Female Reproductive System Disorder 71
Genital Diseases, Female 43

Classifications:



External Ids:

Disease Ontology 12 DOID:229
ICD9CM 34 629.9
MeSH 43 D005831
SNOMED-CT 67 310789003
UMLS 71 C0017411 C0236100

Summaries for Female Reproductive System Disease

Disease Ontology : 12 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary : Female Reproductive System Disease, also known as female reproductive system disorder, is related to uterine anomalies and endometriosis, and has symptoms including menometrorrhagia, mastodynia and breast engorgement. An important gene associated with Female Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Propofol and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and ovary.

Wikipedia : 74 The female reproductive system is made up of the internal and external sex organs that function in... more...

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 33.2 MIR9-1 MIR518D MIR34A MIR30A MIR27A MIR214
2 endometriosis 33.1 MIR200A MIR199A1 MIR145 MIR143 MIR141
3 endometriosis of ovary 33.1 MIR9-1 MIR145 MIR141
4 connective tissue disease 31.1 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
5 ectopic pregnancy 11.2
6 pelvic inflammatory disease 11.2
7 fallopian tube endometriosis 11.2
8 preterm premature rupture of the membranes 11.2
9 endosalpingiosis 11.2
10 endometriosis of intestine 11.2
11 endometriosis of pelvic peritoneum 11.2
12 endometriosis in scar of skin 11.2
13 endometriosis of rectovaginal septum and vagina 11.2
14 vaginal disease 11.2
15 hernia of ovary and fallopian tube 11.2
16 prolapse of female genital organ 11.2
17 amenorrhea 11.2
18 masters-allen syndrome 11.2
19 fallopian tube disease 11.2
20 vulvovaginitis 11.2
21 gynatresia 11.2
22 parovarian cyst 11.2
23 bartholin's gland disease 11.2
24 bartholin's duct cyst 11.2
25 bile duct adenocarcinoma 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR196A1 MIR17
26 leukocyte disease 10.9 MIR30A MIR27A MIR21 MIR199A1 MIR196A1 MIR17
27 glucose metabolism disease 10.9 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
28 ovarian serous carcinoma 10.9 MIR27A MIR214 MIR21 MIR200A MIR199A1 MIR145
29 intestinal benign neoplasm 10.9 MIR21 MIR199A1 MIR196A1 MIR17 MIR145 MIR143
30 acquired metabolic disease 10.9 MIR9-1 MIR30A MIR27A MIR21 MIR200A MIR199A1
31 bone marrow cancer 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
32 biliary tract disease 10.9 MIR9-1 MIR30A MIR199A1 MIR196A1 MIR17 MIR145
33 bile duct disease 10.9 MIR9-1 MIR30A MIR200A MIR199A1 MIR196A1 MIR17
34 ovary epithelial cancer 10.9 MIR9-1 MIR30A MIR21 MIR200A MIR199A1 MIR196A1
35 malignant ovarian surface epithelial-stromal neoplasm 10.9 MIR9-1 MIR30A MIR21 MIR200A MIR199A1 MIR196A1
36 mouth disease 10.9 MIR9-1 MIR21 MIR205 MIR199A1 MIR196A1 MIR193A
37 arteries, anomalies of 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
38 cell type benign neoplasm 10.9 MIR30A MIR21 MIR200A MIR199A1 MIR196A1 MIR17
39 gastrointestinal system benign neoplasm 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR17 MIR143
40 central nervous system cancer 10.9 MIR9-1 MIR34A MIR30A MIR21 MIR199A1 MIR196A1
41 tongue disease 10.9 MIR30A MIR21 MIR199A1 MIR196A1 MIR193A MIR17
42 autonomic nervous system neoplasm 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
43 peripheral nervous system neoplasm 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
44 laryngeal disease 10.9 MIR9-1 MIR34A MIR21 MIR196A1 MIR17 MIR143
45 leukemia, chronic lymphocytic 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
46 spinal disease 10.9 MIR9-1 MIR27A MIR21 MIR199A1 MIR196A1 MIR193A
47 immune system disease 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
48 central nervous system disease 10.9 MIR9-1 MIR34A MIR30A MIR27A MIR21 MIR199A1
49 pharynx cancer 10.9 MIR9-1 MIR30A MIR27A MIR21 MIR199A1 MIR196A1
50 esophageal disease 10.9 MIR34A MIR30A MIR21 MIR200A MIR199A1 MIR196A1

Graphical network of the top 20 diseases related to Female Reproductive System Disease:



Diseases related to Female Reproductive System Disease

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:


menometrorrhagia, mastodynia, breast engorgement, nipple discharge, leukorrhea, vaginal pruritus, vaginal odor, vaginal discomfort, pruritus vulvae, genital itching, perineal pain female, genitalia external painful, menopausal symptoms, vaginal pain, burning feeling vagina, mastoscirrhus, discomfort of vulva

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
7 Platelet Aggregation Inhibitors Phase 4
8 Anesthetics, General Phase 4
9 Anesthetics, Inhalation Phase 4
10 Anesthetics, Intravenous Phase 4
11 Hormones Phase 4
12 Hormone Antagonists Phase 4
13 Progestins Phase 4
14 Psychotropic Drugs Phase 4
15 Anti-Anxiety Agents Phase 4
16 Hypnotics and Sedatives Phase 4
17 GABA Modulators Phase 4
18 Neurotransmitter Agents Phase 4
19
Icodextrin Approved, Investigational Phase 3 337376-15-5
20
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
21
Ketamine Approved, Vet_approved Phase 2, Phase 3 6740-88-1 3821
22
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
23
Ketoprofen Approved, Vet_approved Phase 2, Phase 3 22071-15-4 3825
24
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
25
Gabapentin Approved, Investigational Phase 2, Phase 3 60142-96-3 3446
26
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
27
Bismuth subsalicylate Approved, Vet_approved Phase 2, Phase 3 14882-18-9 53629521
28
Baclofen Approved Phase 2, Phase 3 1134-47-0 2284
29
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
30
Iodine Approved, Investigational Phase 3 7553-56-2 807
31
Povidone Approved Phase 3 9003-39-8
32
Povidone-iodine Approved Phase 3 25655-41-8
33
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
34
Bevacizumab Approved, Investigational Phase 3 216974-75-3
35
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
36
Chitosan Experimental Phase 3 9012-76-4 71853
37 Hemostatics Phase 3
38 Hypolipidemic Agents Phase 3
39 Chelating Agents Phase 3
40 Lipid Regulating Agents Phase 3
41 Anticholesteremic Agents Phase 3
42 Antimetabolites Phase 3
43 Coagulants Phase 3
44 Analgesics, Non-Narcotic Phase 2, Phase 3
45 Analgesics Phase 2, Phase 3
46 Sodium Channel Blockers Phase 3
47 Adrenergic Agents Phase 2, Phase 3
48 Anesthetics Phase 2, Phase 3
49 Diuretics, Potassium Sparing Phase 3
50 Anesthetics, Local Phase 3

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 A National Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh (Prolift) Unknown status NCT00771225 Phase 4
2 Postoperative Pain After Propofol Sevoflurane Anaesthesia: a Prospective, Randomized, Single-blinded Trial Completed NCT01437462 Phase 4 Sevoflurane;Propofol
3 Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
4 Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the Peripheral Immunology. Double Blind Crossover Study. Recruiting NCT03677336 Phase 4 Dydrogesterone Oral Tablet;Micronized progesterone;Placebo Dydrogesterone oral tablet;Placebo Micronized progesterone
5 Efficacity of Hypnosis Versus Premedication for the Management of Perioperative Anxiety in Gynecological Surgery Not yet recruiting NCT03327506 Phase 4 Alprazolam 0.5 mg
6 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study Unknown status NCT02097446 Phase 3
7 Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) for Intraperitoneal Adhesion in Patient With Gynecological Surgery, a Multicenter Single-blinded, Randomized Study Unknown status NCT03007654 Phase 3
8 Pulmonary Recruitment Maneuver to Reduce Postlaparoscopic Shoulder Pain: Randomized Controlled Trial Completed NCT02596425 Phase 3
9 LIdocaine Gel Versus Plain Lubricating Gel for Pain Reduction During Transrectal Sonography (LIPS) Completed NCT02567838 Phase 3 Lidocaine gel;Placebo
10 Novel Topical Therapies for the Treatment of Genital Pain Completed NCT02099006 Phase 2, Phase 3 Amitriptyline;Baclofen;Ketoprofen;Ketamine;Loperamide;Gabapentin;placebo
11 A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer Recruiting NCT03555422 Phase 3 Selinexor;Placebo
12 Chlorhexidine Gluconate Versus Povidone Iodine for Vaginal Surgical Preparation for Urogynecological Procedures Recruiting NCT04048356 Phase 3 Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
13 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
14 LSH vs. TLH, A Randomized Single Blind Trial Withdrawn NCT00734812 Phase 3
15 Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX Unknown status NCT02338505 Phase 2
16 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
17 Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium Completed NCT00456924 Phase 2 VA2914
18 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
19 A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women Completed NCT00365716 Phase 2
20 A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3) Completed NCT02139267 Phase 2
21 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
22 Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers Completed NCT01523678 Phase 2 Filgrastim;Paclitaxel;Carboplatin
23 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
24 The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus Recruiting NCT03656666 Phase 2 Apremilast;Placebo
25 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
26 Preoperative Warm-up in Gynecologic Surgery Using a Virtual Reality Simulator. Completed NCT01712607 Phase 1
27 To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Intrauterine Surgery in Patient With Gynecological Disease, a Multicenter, Randomized, Double- Blinded Study Unknown status NCT02957500
28 Comparison Between Exclusive Surgical Training Versus Virtual Reality Plus Traditional Training in Surgical Skills of Residents of Obstetrics and Gynecology Unknown status NCT03395821
29 A Prospective Randomized Clinical Trial for Comparing Postoperative Pain Following COX-2 and Prostanoids Expression in Women Who Underwent Laparoscopic Surgery for Female Genital Disease Unknown status NCT03391570 COX-2 inhibitor;Placebo Oral Tablet
30 Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population Unknown status NCT02178462
31 Comparison of Volume- and Pressure- Controlled Ventilation With Laryngeal Mask Airway Guardian in Obese Patients Undergoing Laparoscopic Gynecologic Surgery—A Perspective, Randomized, Blind Trial Unknown status NCT02097628
32 Efficacy of Intraoperative Superior Hypogastric Plexus Blockade for Postoperative Pain in Laparoscopic Hysterectomy Unknown status NCT03427840
33 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Unknown status NCT03016039
34 Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates Unknown status NCT01271400
35 Measuring the Mechanism of Incontinence With Urethral Pressure Reflectometry, Before and After Genital Prolapse Surgery Unknown status NCT02050568
36 An Evaluation of the Safety and TechnIcal Feasibility Of the NelLa Women's Care Line for Female Gynecological ExaminaTions and Procedures (VIOLET) Completed NCT03123367
37 Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects Completed NCT02747641
38 A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy Completed NCT01526668
39 Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers Completed NCT02233283
40 Eeva Continued Access Study. Completed NCT01617993
41 Resilience and Quality of Life in Patients With Gynaecological Carcinomas and Chronic Gynaecological Diseases: A Pilot Study Completed NCT03916445
42 An Open-label Study to Evaluate Clinical Performance of Gedea Pessary in Adult Women With Vulvovaginal Candidiasis Completed NCT03761628
43 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
44 Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche Completed NCT01523652
45 A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse Completed NCT02642835
46 Impact of Football Matches on the Emergency Admissions of a Level III Maternity During EURO 2016 Completed NCT03984617
47 Study on the Antiaging Effect of Chinese Herb Drink Completed NCT02634242
48 Comparison of Cosmesis, Patient Satisfaction and Quality of Life in Patients Undergoing Robot Assisted Versus Conventional Laparoscopic Surgery for Bening Gynecologic Disorders: a Prospective Trial Completed NCT04064216
49 Ultrasonic Versus Monopolar Energy-based Surgical Device in Colpotomy During Total Laparoscopic Hysterectomy in Terms of Surgical Smoke and Lateral Thermal Damage: a Randomized Controlled Trial (ULMOST Trial) Completed NCT02729272
50 Phase 4 Study of Optimal Dose of Haloperidol Completed NCT01639599 Dexamethasone iv injection;Dexamethasone, haloperidol;Dexamethasone, haloperidol

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Genetic Tests for Female Reproductive System Disease

Anatomical Context for Female Reproductive System Disease

MalaCards organs/tissues related to Female Reproductive System Disease:

40
Uterus, Cervix, Ovary, Colon, Liver, Breast, Testes

Publications for Female Reproductive System Disease

Articles related to Female Reproductive System Disease:

# Title Authors PMID Year
1
[Analysis on reproductive health status and influencing factors of female workers of pharmaceutical industry in Gansu province]. 61
22356709 2011

Variations for Female Reproductive System Disease

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Pathways for Female Reproductive System Disease

Pathways related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34A MIR30A MIR27A MIR214 MIR21
2 10.07 MIR199A1 MIR145

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR30A MIR27A MIR21 MIR205 MIR199A1 MIR17
2 extracellular vesicle GO:1903561 9.17 MIR34A MIR30A MIR27A MIR214 MIR21 MIR193A

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 MIR27A MIR214 MIR21 MIR17
2 positive regulation of angiogenesis GO:0045766 9.86 MIR30A MIR21 MIR199A1 MIR143
3 negative regulation of cell migration GO:0030336 9.85 MIR9-1 MIR34A MIR214 MIR21
4 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR199A1 MIR196A1 MIR193A
5 positive regulation of blood vessel endothelial cell migration GO:0043536 9.75 MIR30A MIR200A MIR143
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.7 MIR21 MIR199A1 MIR145
7 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR27A MIR214 MIR21 MIR17
8 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR34A MIR214 MIR21
9 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.63 MIR34A MIR17
10 negative regulation of cardiac muscle hypertrophy GO:0010614 9.63 MIR21 MIR145
11 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.63 MIR27A MIR199A1 MIR17
12 negative regulation of angiogenesis GO:0016525 9.63 MIR34A MIR214 MIR21 MIR193A MIR145 MIR143
13 regulation of smooth muscle contraction GO:0006940 9.62 MIR145 MIR143
14 angiotensin-activated signaling pathway GO:0038166 9.61 MIR145 MIR143
15 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.61 MIR27A MIR21
16 positive regulation of connective tissue replacement GO:1905205 9.61 MIR34A MIR214 MIR199A1
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.6 MIR21 MIR17
18 negative regulation of lamellipodium assembly GO:0010593 9.59 MIR214 MIR196A1
19 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR214 MIR199A1 MIR17
20 gene silencing by miRNA GO:0035195 9.58 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR27A
21 aorta smooth muscle tissue morphogenesis GO:0060414 9.57 MIR145 MIR143
22 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR205 MIR199A1 MIR17
23 regulation of phenotypic switching GO:1900239 9.54 MIR145 MIR143
24 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.51 MIR17 MIR143
25 positive regulation of metalloendopeptidase activity GO:1904685 9.5 MIR21 MIR205 MIR17
26 miRNA mediated inhibition of translation GO:0035278 9.5 MIR9-1 MIR30A MIR27A MIR21 MIR205 MIR17
27 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.49 MIR145 MIR143

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.55 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR27A

Sources for Female Reproductive System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....